{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:02:07Z","timestamp":1769835727659,"version":"3.49.0"},"reference-count":42,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Imatinib has been investigated for the treatment of systemic sclerosis (SSc) because of its ability to inhibit the platelet-derived growth factor receptor and transforming growth factor-\u03b2 signaling pathways, which have been implicated in SSc pathogenesis. In a 12-month open-label clinical trial assessing the safety and efficacy of imatinib in the treatment of diffuse cutaneous SSc (dcSSc), significant improvements in skin thickening were observed. Here, we report our analysis of sera collected during the clinical trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We measured the levels of 46 cytokines, chemokines, and growth factors in the sera of individuals with dcSSc using Luminex and ELISA. Autoantigen microarrays were used to measure immunoglobulin G reactivity to 28 autoantigens. Elastic net regularization was used to identify a signature that was predictive of clinical improvement (reduction in the modified Rodnan skin score \u2265 5) during treatment with imatinib. The signature was also tested using sera from a clinical trial of nilotinib, a tyrosine kinase inhibitor that is structurally related to imatinib, in dcSSc.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>The elastic net algorithm identified a signature, based on levels of CD40 ligand, chemokine (C-X-C motif) ligand 4 (CXCL4), and anti-PM\/Scl-100, that was significantly higher in individuals who experienced clinical improvement than in those who did not (p = 0.0011). The signature was validated using samples from a clinical trial of nilotinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Identification of patients with SSc with the greatest probability of benefit from treatment with imatinib has the potential to guide individualized treatment. Validation of the signature will require testing in randomized, placebo-controlled studies.<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"Clinicaltrials.gov\" ext-link-type=\"uri\" xlink:type=\"simple\">Clinicaltrials.gov<\/jats:ext-link><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00555581\">NCT00555581<\/jats:ext-link>and<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01166139\">NCT01166139<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.160833","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T00:10:44Z","timestamp":1489623044000},"page":"631-638","source":"Crossref","is-referenced-by-count":20,"title":["Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment"],"prefix":"10.3899","volume":"44","author":[{"given":"D. James","family":"Haddon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah E.","family":"Wand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin A.","family":"Jarrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Spiera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Utz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica K.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorinda S.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2017,3,15]]},"reference":[{"key":"2018112909365944000_44.5.631.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(03)00023-1"},{"key":"2018112909365944000_44.5.631.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24221"},{"key":"2018112909365944000_44.5.631.3","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/BOR.0b013e32833f1105","article-title":"Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis","volume":"22","author":"Gordon","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"2018112909365944000_44.5.631.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143974"},{"key":"2018112909365944000_44.5.631.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.30549"},{"key":"2018112909365944000_44.5.631.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.30548"},{"key":"2018112909365944000_44.5.631.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11186.x"},{"issue":"Suppl 10","key":"2018112909365944000_44.5.631.8","first-page":"560","article-title":"A multi-center, open-label, proof of concept study of imatinib mesylate demonstrates no benefit for the treatment of fibrosis in patients with early, diffuse systemic sclerosis","volume":"62","author":"Distler","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2018112909365944000_44.5.631.9","doi-asserted-by":"publisher","DOI":"10.1186\/ar4606"},{"issue":"Suppl 10","key":"2018112909365944000_44.5.631.10","first-page":"S239","article-title":"Evaluation of an imatinib response gene signature in patients with systemic sclerosis","volume":"62","author":"Chung","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2018112909365944000_44.5.631.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.06.001"},{"key":"2018112909365944000_44.5.631.12","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00028209"},{"key":"2018112909365944000_44.5.631.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02642.x"},{"key":"2018112909365944000_44.5.631.14","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-004-0061-9"},{"key":"2018112909365944000_44.5.631.15","doi-asserted-by":"publisher","DOI":"10.1038\/nm0302-295"},{"key":"2018112909365944000_44.5.631.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.050187"},{"key":"2018112909365944000_44.5.631.17","first-page":"S213","article-title":"Nilotinib (Tasigna\u2122) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial","volume":"17","author":"Gordon","year":"2015","journal-title":"Arthritis Rheum"},{"key":"2018112909365944000_44.5.631.18","unstructured":"US National Institutes of Health . Nilotinib in the treatment of systemic sclerosis. NCT01166139 . [Internet. Accessed February 28, 2017.] Available from: https:\/\/clinicaltrials.gov\/ct2\/results?term=NCT01166139&Search=Search."},{"key":"2018112909365944000_44.5.631.19","unstructured":"R Core Team . The R project for statistical computing. [Internet. Accessed February 1, 2017.] Available from: www.R-project.org"},{"key":"2018112909365944000_44.5.631.20","unstructured":"Tibshirani R Chu G Narasimhan B samr Li J : SAM: significance analysis of microarrays, 2.0 ed. [Internet. Accessed February 1, 2017.] Available from: cran.r-project.org\/web\/packages\/samr\/index.html"},{"key":"2018112909365944000_44.5.631.21","unstructured":"Kolde R . Pretty heatmaps, 0.7.7 ed. [Internet. Accessed February 1, 2017.] Available from: cran.r-project.org\/web\/packages\/pheatmap\/index.html"},{"key":"2018112909365944000_44.5.631.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9868.2005.00503.x"},{"key":"2018112909365944000_44.5.631.23","unstructured":"Hastie T Tibshirani R Narasimhan B Chu G . impute: Imputation for microarray data, 3.2 ed. [Internet. Accessed February 1, 2017.] Available from: bioconductor.org\/packages\/release\/bioc\/html\/impute.html"},{"key":"2018112909365944000_44.5.631.24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J R Statist Soc B"},{"key":"2018112909365944000_44.5.631.25","unstructured":"Sing T Sander O Beerenwinkel N Lengauer T . ROCR: visualizing the performance of scoring classifiers, 1.0\u20137 ed [Internet. Accessed February 1, 2017.] Available from: cran.r-project.org\/web\/packages\/ROCR\/index.html"},{"key":"2018112909365944000_44.5.631.26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.091062498"},{"key":"2018112909365944000_44.5.631.27","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21968"},{"key":"2018112909365944000_44.5.631.28","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21716"},{"key":"2018112909365944000_44.5.631.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.37742"},{"issue":"Suppl 71","key":"2018112909365944000_44.5.631.30","first-page":"S44","article-title":"CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment","volume":"30","author":"Bandinelli","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909365944000_44.5.631.31","doi-asserted-by":"publisher","DOI":"10.1186\/ar3271"},{"key":"2018112909365944000_44.5.631.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2009.11.008"},{"key":"2018112909365944000_44.5.631.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114576"},{"key":"2018112909365944000_44.5.631.34","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes090"},{"key":"2018112909365944000_44.5.631.35","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.2000.0387"},{"key":"2018112909365944000_44.5.631.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.020040"},{"key":"2018112909365944000_44.5.631.37","first-page":"514","article-title":"Elevated circulating CD40L concentrations in patients with systemic sclerosis","volume":"31","author":"Komura","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909365944000_44.5.631.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00751.x"},{"key":"2018112909365944000_44.5.631.39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu216"},{"key":"2018112909365944000_44.5.631.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.05.011"},{"key":"2018112909365944000_44.5.631.41","doi-asserted-by":"publisher","DOI":"10.1186\/ar2614"},{"key":"2018112909365944000_44.5.631.42","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199211000-00001"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.160833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T00:55:35Z","timestamp":1719104135000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.160833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,15]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,1]]},"published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.3899\/jrheum.160833"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.160833","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,15]]}}}